Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.

Clinical targeting of the altered metabolism of tumor cells has long been considered an attractive hypothetical approach. However, this strategy has yet to perform well clinically. Metabolic redundancy is among the limitations on effectiveness of many approaches, engendering intrinsic single-agent r...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Moises O Guardado Rivas, Shawn D Stuart, Daniel Thach, Michael Dahan, Robert Shorr, Zuzana Zachar, Paul M Bingham
Format:	Artigo
Język:	Inglês
Wydane:	Public Library of Science (PLoS) 2022-01-01
Seria:	PLoS ONE
Dostęp online:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0269620&type=printable
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!